Advertisement

Genetic Alterations in Colorectal Cancer in Older Patients

  • Zenia Saridaki
  • John SouglakosEmail author
Chapter

Abstract

Colorectal cancer is typically associated with advanced age, with an estimated median age at onset which reaches 70 years of age in the western population. Limited data are available regarding the differences in genetic and epigenetic alterations in colonic carcinogenesis between younger and older patients. Some studies suggest that mutation status in critical genes, such as KRAS, BRAF, or PIK3CA/PTEN, is different, depending of the age at diagnosis of colorectal cancer. These data provide the evidence that distinct genetic mechanisms are implicated in the somatic development of colorectal cancer in younger and older patients.

Keywords

Ageing Genetic alteration Colon cancer Elderly patients 

References

  1. 1.
    Amado RG, Wolf M, Peeters M, Van CE, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Apfeld J, O’Connor G, McDonagh T, DiStefano PS, Curtis R. The AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in C. elegans. Genes Dev. 2004;18:3004–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Arum O, Bonkowski MS, Rocha JS, Bartke A. The growth hormone receptor gene-disrupted mouse fails to respond to an intermittent fasting diet. Aging Cell. 2009;8:756–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Ayyadevara S, Tazearslan C, Bharill P, Alla R, Siegel E, Shmookler Reis RJ. Caenorhabditis elegans PI3K mutants reveal novel genes underlying exceptional stress resistance and lifespan. Aging Cell. 2009;8:706–25.PubMedCrossRefGoogle Scholar
  5. 5.
    Bartke A. Insulin and aging. Cell Cycle. 2008;7:3338–43.PubMedCrossRefGoogle Scholar
  6. 6.
    Berg M, Danielsen SA, Ahlquist T, Merok MA, Agesen TH, Vatn MH, Mala T, Sjo OH, Bakka A, Moberg I, Fetveit T, Mathisen O, Husby A, Sandvik O, Nesbakken A, Thiis-Evensen E, Lothe RA. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS One. 2010;5:e13978.PubMedCrossRefGoogle Scholar
  7. 7.
    Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de BF, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2008;27(5):663–71.PubMedCrossRefGoogle Scholar
  8. 8.
    Carey JR, Liedo P, Orozco D, Vaupel JW. Slowing of mortality rates at older ages in large medfly cohorts. Science. 1992;258:457–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Cheng YW, Pincas H, Bacolod MD, Schemmann G, Giardina SF, Huang J, Barral S, Idrees K, Khan SA, Zeng Z, Rosenberg S, Notterman DA, Ott J, Paty P, Barany F. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res. 2008;14:6005–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374:1196–208.PubMedCrossRefGoogle Scholar
  11. 11.
    Clancy DJ, Gems D, Hafen E, Leevers SJ, Partridge L. Dietary restriction in long-lived dwarf flies. Science. 2002;296:319.PubMedCrossRefGoogle Scholar
  12. 12.
    Curtsinger JW, Fukui HH, Townsend DR, Vaupel JW. Demography of genotypes: failure of the limited life-span paradigm in Drosophila melanogaster. Science. 1992;258:461–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De DS, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Dotan E, Nicolas E, Devarajan K, Beck RJ, Cohen SJ. A pilot study evaluating peripheral blood lymphocyte telomere length in elderly versus young patients with colorectal cancer (CRC). In: 2012 Gastrointestinal cancers symposium. J Clin Oncol 30. 2012(suppl 4; abstr 512).Google Scholar
  15. 15.
    Douillard J, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel ME, Humblet Y, Cunningham D, Wolf M, Gansert JL. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. In: 2010 Gastrointestinal cancers symposium. Ann Oncol Supp. 2009.Google Scholar
  16. 16.
    Ewbank DC. Differences in the association between apolipoprotein E genotype and mortality across populations. J Gerontol A Biol Sci Med Sci. 2007;62:899–907.PubMedCrossRefGoogle Scholar
  17. 17.
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.PubMedCrossRefGoogle Scholar
  18. 18.
    French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008;14:3408–15.PubMedCrossRefGoogle Scholar
  19. 19.
    Georgiades IB, Curtis LJ, Morris RM, Bird CC, Wyllie AH. Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability. Oncogene. 1999;18:7933–40.PubMedCrossRefGoogle Scholar
  20. 20.
    Gerdes LU, Jeune B, Ranberg KA, Nybo H, Vaupel JW. Estimation of apolipoprotein E genotype-specific relative mortality risks from the distribution of genotypes in centenarians and middle-aged men: apolipoprotein E gene is a “frailty gene,” not a “longevity gene”. Genet Epidemiol. 2000;19:202–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Greer EL, Dowlatshahi D, Banko MR, Villen J, Hoang K, Blanchard D, Gygi SP, Brunet A. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr Biol. 2007;17:1646–56.PubMedCrossRefGoogle Scholar
  22. 22.
    Hamilton WD. The moulding of senescence by natural selection. J Theor Biol. 1966;12:12–45.PubMedCrossRefGoogle Scholar
  23. 23.
    Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392–5.PubMedGoogle Scholar
  24. 24.
    Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672–80.PubMedCrossRefGoogle Scholar
  25. 25.
    Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology. 2000;119:921–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Herndon LA, Schmeissner PJ, Dudaronek JM, Brown PA, Listner KM, Sakano Y, Paupard MC, Hall DH, Driscoll M. Stochastic and genetic factors influence tissue-specific decline in ageing C. elegans. Nature. 2002;419:808–14.PubMedCrossRefGoogle Scholar
  27. 27.
    Honjoh S, Yamamoto T, Uno M, Nishida E. Signalling through RHEB-1 mediates intermittent fasting-induced longevity in C. elegans. Nature. 2009;457:726–30.PubMedCrossRefGoogle Scholar
  28. 28.
    Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988–93.PubMedCrossRefGoogle Scholar
  29. 29.
    Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature. 2009;458:725–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol. 2004;14:885–90.PubMedCrossRefGoogle Scholar
  31. 31.
    Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.PubMedCrossRefGoogle Scholar
  32. 32.
    Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell. 2005;120:449–60.PubMedCrossRefGoogle Scholar
  33. 33.
    Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A C. elegans mutant that lives twice as long as wild type. Nature. 1993;366:461–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Kenyon CJ. The genetics of ageing. Nature. 2010;464:504–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Li Y, Wang WJ, Cao H, Lu J, Wu C, Hu FY, Guo J, Zhao L, Yang F, Zhang YX, Li W, Zheng GY, Cui H, Chen X, Zhu Z, He H, Dong B, Mo X, Zeng Y, Tian XL. Genetic association of FOXO1A and FOXO3A with longevity trait in Han Chinese populations. Hum Mol Genet. 2009;18:4897–904.PubMedCrossRefGoogle Scholar
  36. 36.
    Li Y, Xu W, McBurney MW, Longo VD. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab. 2008;8:38–48.PubMedCrossRefGoogle Scholar
  37. 37.
    Liang JT, Huang KC, Cheng AL, Jeng YM, Wu MS, Wang SM. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg. 2003;90:205–14.PubMedCrossRefGoogle Scholar
  38. 38.
    Mair W, Goymer P, Pletcher SD, Partridge L. Demography of dietary restriction and death in Drosophila. Science. 2003;301:1731–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Oeppen J, Vaupel JW. Demography. Broken limits to life expectancy. Science. 2002;296:1029–31.PubMedCrossRefGoogle Scholar
  40. 40.
    Pawlikowska L, Hu D, Huntsman S, Sung A, Chu C, Chen J, Joyner AH, Schork NJ, Hsueh WC, Reiner AP, Psaty BM, Atzmon G, Barzilai N, Cummings SR, Browner WS, Kwok PY, Ziv E. Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell. 2009;8:460–72.PubMedCrossRefGoogle Scholar
  41. 41.
    Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93:53–62.PubMedCrossRefGoogle Scholar
  42. 42.
    Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18.PubMedCrossRefGoogle Scholar
  43. 43.
    Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW, Leppert M, Slattery ML. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001;10:917–23.PubMedGoogle Scholar
  44. 44.
    Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One. 2011;6:e15980.PubMedCrossRefGoogle Scholar
  45. 45.
    Sierra F, Hadley E, Suzman R, Hodes R. Prospects for life span extension. Annu Rev Med. 2009;60:457–69.PubMedCrossRefGoogle Scholar
  46. 46.
    Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009;101:465–72.PubMedCrossRefGoogle Scholar
  47. 47.
    Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563–72.PubMedCrossRefGoogle Scholar
  48. 48.
    Tomas-Loba A, Flores I, Fernandez-Marcos PJ, Cayuela ML, Maraver A, Tejera A, Borras C, Matheu A, Klatt P, Flores JM, Vina J, Serrano M, Blasco MA. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell. 2008;135:609–22.PubMedCrossRefGoogle Scholar
  49. 49.
    Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.PubMedCrossRefGoogle Scholar
  50. 50.
    Vaupel JW. Biodemography of human ageing. Nature. 2010;464:536–42.PubMedCrossRefGoogle Scholar
  51. 51.
    Vaupel JW, Loichinger E. Redistributing work in aging Europe. Science. 2006;312:1911–3.PubMedCrossRefGoogle Scholar
  52. 52.
    Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789–99.PubMedCrossRefGoogle Scholar
  53. 53.
    Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–13.PubMedCrossRefGoogle Scholar
  54. 54.
    Zbuk K, Sidebotham EL, Bleyer A, La Quaglia MP. Colorectal cancer in young adults. Semin Oncol. 2009;36:439–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Laboratory of Tumor Cell Biology, Medical SchoolUniversity of CreteHeraklion, CreteGreece
  2. 2.Medical OncologyMedical School, University of CreteHeraklion, CreteGreece

Personalised recommendations